HHS enumerates qui tam fraud cases

U.S. officials are tracking 180 whistleblower cases that accuse drugmakers of defrauding the government via pricing or marketing of prescription meds, the Department of Health and Human Services said. Report 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.